Vertex Pharmaceuticals
Registered Principal Details
Business Or Interest:
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.
Lobbying Interests:
Engage on access issues relating to non-opioid Pain Alternatives; access to healthcare; Awareness activities specific to Cystic Fibrosis, Sickle Cell Disease, T1D, Kidney Disease, and Pain.
CEO Name:
Reshma Kewalramani
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.
Lobbying Interests:
Engage on access issues relating to non-opioid Pain Alternatives; access to healthcare; Awareness activities specific to Cystic Fibrosis, Sickle Cell Disease, T1D, Kidney Disease, and Pain.
CEO Name:
Reshma Kewalramani
Contact
AP
Abigail Parta
50 Northern Avenue
Boston, MA 20001
(312) 835-9997
compliance_wi_vertex@multistate.us
http://www.vrtx.com
50 Northern Avenue
Boston, MA 20001
(312) 835-9997
compliance_wi_vertex@multistate.us
http://www.vrtx.com
Authorized Lobbyists
Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
---|
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 173
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
4/14/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date4/14/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 203
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
4/21/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date4/21/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Budget Bill Subjects
Biennial budget bill treatment of matter relating to
Health Services: Medicaid Services
Health Services: Medicaid Services
Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Biennial budget bill treatment of matter relating to
Insurance: Departmentwide
Insurance: Departmentwide
Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Biennial budget bill treatment of matter relating to
Insurance: Supervision of the Insurance Industry
Insurance: Supervision of the Insurance Industry
Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to the treatment of nonopioid drugs and the development of a pain management access plan
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to the treatment of nonopioid drugs and the development of a pain management access plan
Development, drafting or introduction of a proposal relating to the treatment of nonopioid drugs and the development of a pain management access plan
Action Intended To Affect
Legislative matter
Notification Date
3/12/2025
First Communication Date
3/6/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Legislative matter
Notification Date
3/12/2025
First Communication Date
3/6/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to sickle disease awareness month.
Development, drafting or introduction of a proposal related to sickle disease awareness month.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
2025 January - June |
Total | |
---|---|---|
Total Lobbying Expenditures | 2025 January - June $24,000.00 |
Total $24,000.00 |
Total Hours Communicating | 2025 January - June 4.50 |
Total 4.50 |
Total Hours Other | 2025 January - June 38.50 |
Total 38.50 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
2025 January - June |
2025 July - December |
2026 January - June |
2026 July - December |
Total |
---|---|---|---|---|
2025 January - June 10% |
2025 July - December |
2026 January - June |
2026 July - December |
Total 9% |
Budget Bill Subjects
2025 January - June |
2025 July - December |
2026 January - June |
2026 July - December |
Total |
---|---|---|---|---|
2025 January - June 10% |
2025 July - December |
2026 January - June |
2026 July - December |
Total 9% |
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
2025 January - June |
2025 July - December |
2026 January - June |
2026 July - December |
Total |
---|---|---|---|---|
2025 January - June 20% |
2025 July - December |
2026 January - June |
2026 July - December |
Total 20% |
2025 January - June |
2025 July - December |
2026 January - June |
2026 July - December |
Total |
---|---|---|---|---|
2025 January - June 20% |
2025 July - December |
2026 January - June |
2026 July - December |
Total 20% |
Development, drafting or introduction of a proposal relating to the treatment of nonopioid drugs and the development of a pain management access plan
2025 January - June |
2025 July - December |
2026 January - June |
2026 July - December |
Total |
---|---|---|---|---|
2025 January - June 40% |
2025 July - December |
2026 January - June |
2026 July - December |
Total 40% |
Minor Efforts
No minor efforts found.
Other Matters
No other matters found.